Day: January 19, 2023

Queen Elizabeth II, the UK’s longest-serving monarch, has died at Balmoral aged 96, after reigning for 70 years. The Queen came to the throne in 1952 and witnessed enormous social change. With her death, her eldest son Charles, the former Prince of Wales, will lead the country in mourning as the new King and head […]

Continue Reading

The landmark 14-Site study on the role of Next-Generation Sequencing in Periprosthetic Joint Infections has been acknowledged by the journal as being one of the ten that “will have the greatest impact on patient care.”…

Continue Reading

AQuity Solutions’ QCodeAI significantly boosts coder accuracy and productivity for improved overall financial performance.

CARY, N.C. – January 19, 2023 – (Newswire.com)

AQuity Solutions confirmed the successful launch of QCodeAI with early adopters of their QCode platform. QCodeAI leverages the latest developments in machine learning ML and natural language processing NLP to automate key coding processes that improve coder productivity and accuracy for reduced turnaround times and labor costs. Adding AI-based Autonomous Coding to support its expanding portfolio of premium coding solutions, QCodeAI delivers increased accuracy, reduced denials, and proper revenue capture, with early adopters consistently seeing 40% to 75% efficiency gains in productivity.

“We are delighted to launch QCodeAI at this critical point in our industry with financial pressures and labor challenges at top of mind to our expanding client base,” shared Kashyap Joshi, CEO. “Our solution provides measurable and material impact to help alleviate these pressures impacting our clients and was developed with strict adherence to HIPAA-compliant program architecture. QCodeAI effectively delivers needed relief to the pressured coding labor market without sacrificing quality or security requirements.”

“Our implementation process for QCodeAI meets our clients at their state of readiness, as we partner with our clients to identify high-impact areas to drive early wins,” added Cindy Nicholas, VP Coding. “QCodeAI also captures all audit trail data for accuracy validation, compliance, training, and appeals’ basis, a critical value-add for our clients.”

About AQuity

Headquartered in Cary, NC, AQuity provides solutions for 21 of the Top 25 and over half of the Top 250 Health Systems in the United States. AQuity employs over 7,500 documentation capture and medical coding professionals across the United States, India, Australia, Canada, and the U.K. With over 45 years of experience in service and technology solutions for healthcare, AQuity is recognized year after year by KLAS and Black Book as a leading vendor in multiple disciplines. AQuity is privately held. https://aquitysolutions.com/

Contact Information:

Dale Kivi

Senior Director of Communications
[email protected]

804.339.9017

Press Release Service
by
Newswire.com

Original Source:

AQuity Launches QCode®AI Autonomous Coding to Support Rapidly Growing Coding Solutions Business

Continue Reading

In partnership with the New Orleans Mayor’s office, Avenues Recovery Center announced today the return of their popular Sober Safe Spot event at the February Mardi Gras parades.

NEW ORLEANS – January 19, 2023 – (Newswire.com)

Last year’s inaugural Sober Safe Spots drew hundreds of revelers committed to the recovery community to the specially marked-off locations along parade routes. The safe spots provided an opportunity for people in active recovery and their loved ones to celebrate the joy and culture of Mardi Gras in a sober and safe environment. An overwhelmingly positive response from the community drove Avenues Recovery to make Sober Safe Spot an annual event and part of the fabric of Mardi Gras.

Sober Safe Spot will be manned by Avenues Recovery alumni, a strong community of recovery heroes who are always willing to go above and beyond to help out others in recovery. 

“One of the most beautiful parts of Sober Safe Spot is that it was conceived and is coordinated by our alumni,” said Ashley Duncan, Alumni and Intake Coordinator at Avenues Recovery of Louisiana. “They have gained so much from their own recovery journeys and are determined to give back.” 

The gathering spot will be set aside from Feb. 10 through 21 and is open to everyone in the community who wishes to support addiction treatment.

“We are excited to once again partner with Avenues Recovery for this important and necessary addition to our ongoing Mardi Gras safety operations,” said Mayor LaToya Cantrell. “My administration remains committed to meeting our people where they are and directly addressing each and every critical need throughout our city. Our ongoing partnership with Avenues Recovery and their Sober Safe Spot initiative gives us a meaningful opportunity to support our community in addiction treatment and recovery, which will aid us in creating a more inclusive, safe, healthy and thriving city.” 

All participants will be given specially made T-shirts and other fun swag, allowing them to proudly display their choice to have fun in recovery. A white flag emblazoned with the Sober Safe Spot logo will fly at the neutral ground at the corner of Napoleon Avenue and St. Charles Avenue, making the gathering place easily identifiable to all interested in joining. More details and information can be found on the Sober Safe Spot page on the Avenues Recovery website. 

“There are no requirements to joining Sober Safe Spot other than staying sober and having fun,” added Duncan. “We hope to see you all there.”

Press availability upon request or at the event.

###

Avenues Recovery Centers is a fully accredited substance abuse treatment network founded in 2016 and serving communities nationwide. They are staffed by clinical and medical professionals, focused on creating positive outcomes for their clients.

View Website

Contact Information:

Rachel Alter

Marketing Director
[email protected]

773-562-1457

Press Release Service
by
Newswire.com

Original Source:

Sober Safe Spot at Mardi Gras Returns to New Orleans

Continue Reading

Funds will help improve infrastructure and increase capacity.

Project Open Hand Serving Meals with Love and Meals that Heal to individuals in the…

Continue Reading

DURHAM, N.C. – January 19, 2023 – (Newswire.com)

Male Contraceptive Initiative (MCI), a 501(c)(3) non-profit, has partnered with the pharmaceutical company Eppin Pharma to provide a Program Related Investment (PRI) of up to $800,000 to support clinical trial activities for the company’s novel short-term, non-hormonal oral male contraceptive pill.

This is the latest PRI from Male Contraceptive Initiative and represents the organization’s continued evolution as it seeks to expand its support of the male contraception research and development community. “We are very excited about adding additional program related investments to our portfolio as a means of accelerating male contraceptive product development through a collaborative, ‘team science’ approach. Returns on these investments will go directly back into supporting research efforts to continue driving the field of non-hormonal male contraception forward,” said MCI Executive Director Heather Vahdat. “Eppin Pharma is a particularly exciting investment opportunity as they have been integral at advancing the non-hormonal male contraceptive field in an effort to revolutionize family planning by providing reproductive equity to men who still have to rely on only two methods of birth control: condoms and vasectomy,” Ms. Vahdat added.

Eppin Pharma’s lead male contraceptive candidate is a small organic compound that binds to EPPIN, a protein on the surface of human sperm, resulting in the loss of the sperm’s ability to properly function. The non-hormonal treatment Eppin Pharma is developing is intended to be fast-acting and does not affect the production of sperm. 

MCI’s investment in Eppin Pharma will be used to establish proof-of-concept of safety and feasibility of their contraceptive method as they prepare for human clinical trials. This is an important first step prior to conducting a larger efficacy study required for gaining regulatory approval and widespread consumer access to the therapeutic. 

“We have been excited about Eppin’s work since 2019, when we provided them with an initial grant to advance their work. Given the success of their science to date, we are pleased to expand our collaboration as Eppin Pharma represents the forefront of pharmacologic, non-hormonal male contraceptive methods,” said MCI Research Director Dr. Logan Nickels. 

“We are grateful to MCI for their dedication to supporting innovation in male contraception and for recognizing the transformative potential of our work,” said Dr. Michael O’Rand, Eppin Pharma’s President & Chief Executive Officer. “At Eppin Pharma, we are dedicated to developing new options for men who desire to take control of their fertility and we look forward to advancing our method to clinical trials in the near future,” added Dr. O’Rand.

With over $10 million invested in product development, MCI seeks to advance male contraceptive research projects to market in order to achieve its organizational vision of “Reproductive Autonomy for All”. MCI’s mission is, “To empower men, and couples, to fully contribute to family planning goals by providing them the resources they need for reproductive autonomy.”

Contact Information:

Kevin Shane

Communications & Design Director
[email protected]

5853072270

Press Release Service
by
Newswire.com

Original Source:

Male Contraceptive Initiative Invests in Eppin Pharma to Support Clinical Trials for a Non-Hormonal Male Contraceptive

Continue Reading

In vitro antimicrobial resistance test enables clinical labs to deliver targeted therapeutic results days faster than the current standard of care, clearing the path for personalized antibiotic therapies

BOSTON – January 19, 2023 – (Newswire.com)

Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Next Generation Phenotyping (NGP) System — a rapid antibiotic susceptibility (AST) testing platform that provides targeted therapeutic results days faster than the current standard of care. 

The FDA clearance is for Selux Diagnostics’ in vitro antimicrobial resistance test, which determines a bacteria’s susceptibility to 14 specific antimicrobial agents on the Selux Gram-Positive Panel. Selux’s NGP Gram-Negative panel is currently under review by the FDA. 

“This clearance represents a significant advance in infectious disease care and the fight to address antibiotic resistance. Our groundbreaking Selux NGP System holds the potential to save lives and decrease overreliance on broad-spectrum antibiotics, a key factor contributing to the rise of superbugs. We thank all our employees, partners, and advisors who contributed to this tremendous accomplishment,” said Steve Lufkin, CEO of Selux Diagnostics.

“We have been waiting for true innovation in AST technologies to deliver rapid results that are accurate according to the latest FDA guidelines and include newly approved antibiotics,” said James S. Lewis II, PharmD, FIDSA, co-director of antibiotic stewardship at Oregon Health and Science University, and chair, CLSI Antimicrobial Susceptibility Testing Subcommittee. “I am enthusiastic that the Selux NGP System addresses these critical needs and will become an essential tool for directing personalized therapies for infected patients.”

Experts predict that without a significant change in today’s treatment options, deaths from superbugs will surpass deaths from cancer by 2050. Selux is confronting this global health crisis head-on by redefining the speed and performance of AST, the critical diagnostic test that informs personalized antibiotic therapy.

For more information on the Selux NGP System, visit www.seluxdx.com.

Acknowledgment

This platform has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); and Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201800013C.

About Selux Diagnostics 

Selux Diagnostics is transforming patient care by accelerating the selection of personalized antimicrobial therapy for all Infectious Disease patients. This advance will save lives, shorten hospital stays, and combat the growing antibiotic resistance epidemic by decreasing the overuse of broad-spectrum agents. Learn more at www.seluxdx.com.

Contact Information:

Andrea LePain
[email protected]

617-894-1153

Press Release Service
by
Newswire.com

Original Source:

FDA Clears ‘Selux NGP System’ for Rapid Antibiotic Susceptibility Testing

Continue Reading